Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR -Activating Mutation.

Autor: Nishihara, Shigetoshi1 (AUTHOR) s.nishi@med.showa-u.ac.jp, Yamaoka, Toshimitsu2,3 (AUTHOR) ohmorit@med.showa-u.ac.jp, Ishikawa, Fumihiro4 (AUTHOR) f-ishikawa@pharm.showa-u.ac.jp, Ohmori, Tohru3 (AUTHOR) koichi-a@med.showa-u.ac.jp, Ando, Koichi3 (AUTHOR) k-sojiro@med.showa-u.ac.jp, Kusumoto, Sojiro3 (AUTHOR) ookiyookiy@med.showa-u.ac.jp, Kishino, Yasunari3 (AUTHOR) r.manabe@med.showa-u.ac.jp, Manabe, Ryo3 (AUTHOR) sagarah@med.showa-u.ac.jp, Hasebe, Yuki2 (AUTHOR) tsurutaj@med.showa-u.ac.jp, Sagara, Hironori3 (AUTHOR), Yoshida, Hitoshi1 (AUTHOR) hyoshida@med.showa-u.ac.jp, Tsurutani, Junji2 (AUTHOR)
Zdroj: Cells (2073-4409). Jul2022, Vol. 11 Issue 14, pN.PAG-N.PAG. 17p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje